Views & Analysis 5 years of biosimilars in the US: what have we learned? Biologics have created revolutionary treatment options that have transformed the care journey for hundreds of millions of patients worldwide.
Views & Analysis Who could replace Sir Andrew Dillon at NICE? With Sir Andrew Dillon announcing his retirement as chief executive of NICE, pharmaphorum discusses potential replacements for the man who is arguably the most influential figure in health